

References

I-16

1. Bildik G, Akin N, Senbabaoglu F, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. *Hum Reprod.* 2015;2912-2925.
2. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. 2019. Leuprolide Acetate.
3. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. 2019. Leuprolide Acetate for Depot Suspension.
4. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. 2019. Histrelin acetate.
5. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. 2019. Triptorelin pamoate.
6. Lupron Depot (leuprolide acetate for depot suspension), for intramuscular use. AbbVie. North Chicago, IL. Revised 06/2016.
7. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.
8. ELIGARD® (leuprolide acetate for injectable suspension) [package insert]. Fort Collins, CO: TOLMAR Inc.:2016.
9. Maru S, Uchino H, Osawa T, Chiba S, Mouri G, & Sazawa A. Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. *PLoS ONE.* 2018;13(5):1-11.
10. Venturelli M, Guatoli G, Omarini C, & Moscetti L. Spotlight on triptorelin in the treatment of premenopausal women in early-stage breast cancer. *Breast Cancer.* 2018;10:39-49.
11. Kittai AS, Blank J, Graff JN. Gonadotropin-releasing hormone antagonists in prostate cancer. *Oncology.* 2018;32(12):599-606.
12. MICROMEDEX®SOLUTIONS Compendia. 2019. Leuprolide
13. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Triptorelin. 2019.
14. MICROMEDEX®SOLUTIONS Compendia. 2019. Triptorelin.
15. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Histrelin. 2019.
16. MICROMEDEX®SOLUTIONS Compendia. 2019. Histrelin.
17. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Leuprolide/norethindrone. 2019.
18. MICROMEDEX®SOLUTIONS Compendia. 2019. Leuprolide/norethindrone.

19. Lupron Depot 11.25 mg (leuprolide acetate for depot suspension), for intramuscular use. AbbVie. North Chicago, IL. Revised 04/2018.
20. Lupron Depot 3.75 mg (leuprolide acetate for depot suspension). AbbVie. North Chicago, IL. Revised 04/2018.
21. Lupron Depot-Ped (leuprolide acetate for depot suspension), injection. AbbVie. North Chicago, IL. Revised 05/2017.
22. Eligard (leuprolide acetate for injectable suspension). TOLMAR Inc. Fort Collins, CO. Revised 02/2016.
23. Lupaneta Pack (leuprolide acetate for depot suspension; norethindrone acetate tablets), co-packaged for intramuscular use and for oral use, respectively. AbbVie. North Chicago, IL. Revised 06/2015.
24. Vantas (histrelin acetate) subcutaneous implant. Endo Pharmaceuticals Solutions Inc. Malvern, PA. Revised 06/2017.
25. Supprelin LA (histrelin acetate implant). Endo Pharmaceuticals Solutions inc. Malvern, PA. Revised 05/2017.
26. Triptodur (triptorelin) for extended-release injectable suspension, for intramuscular use. Arbor Pharmaceuticals, LLC. Atlanta, GA. Revised 09/2017.
27. Trelstar (triptorelin pamoate for injectable suspension), intramuscular use. Allergan. Irvine, CA. Revised 01/2018.
28. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people. *International Journal of Transgenderism*. 2012;13(4):165-232.
29. Radix A, Davis AM. Endocrine treatment of gender-dysphoric/gender-incongruent Persons. *JAMA*. 2017;318(15):1491-1492.
30. Fensolvi (leuprolide acetate) for injection suspension, for subcutaneous use [package insert]. Tolmar, Inc. Fort Collins, CO. Revised 05/2020.
31. Chew D, Anderson J, Williams K, May T, Pang K. Hormonal treatment in young people with gender dysphoria: a systematic review. *Pediatrics*. 2018;141(4):1-18.
32. McKay RR, Ye H, Xie W, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. *Journal of Clinical Oncology*. 2019;37(11):923-931.